Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07414992 · ClinicalTrials.gov registry record · Phase 2
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT07414992: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07414992 is a Phase 2 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07414992, a Phase 2 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).
Interventions
- DRUG Cemiplimab
- RADIATION Stereotactic body radiotherapy
- PROCEDURE Radical cystectomy
- DRUG Cemiplimab and Fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07414992
The ClinicalTrials.gov registry entry for NCT07414992 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cemiplimab is the first listed.
NCT07414992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07414992 about?
NCT07414992 is a clinical study titled "A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer". The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).
What is the current status of trial NCT07414992?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2026-07. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07414992?
The interventions under investigation include: Cemiplimab (DRUG), Stereotactic body radiotherapy (RADIATION), Radical cystectomy (PROCEDURE), Cemiplimab and Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07414992?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.